Last reviewed · How we verify
SERETIDE Rotacaps
At a glance
| Generic name | SERETIDE Rotacaps |
|---|---|
| Also known as | Placebo delivered via a capsule-based inhaler, Physical examination, adverse event (AE) and serious AE assessments, clinical laboratory safety tests (blood and urine), 12-lead electrocardiogram assessment |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. (PHASE1, PHASE2)
- A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SERETIDE Rotacaps CI brief — competitive landscape report
- SERETIDE Rotacaps updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI